Clinical Trials and Research
| Clinical Trials |
Find clinical trials based on cancer types, stage, previous treatment, daily activity, and zip code. |
Why Clinical Trials Matter
Clinical trials are an important step in discovering new ways to diagnose, evaluate, treat, and prevent cancer, and are vital to keeping pace with the rapidly advancing field of oncology.
Trials allow doctors to give their patients the most current, cutting-edge medicines, equipment, procedures, and comfort measures that otherwise might not be available for years. They show researchers what does and doesn’t work in people, and help them decide if the side effects of a new treatment are acceptable when weighed against the benefits.
More than 10 million cancer survivors are living in the U.S. today, and most owe their survival to patients who took part in clinical trials before them.
National Cancer Institute
Community Cancer Center Program (NCCCP)
St. Luke’s MSTI was selected in 2010 as a National Cancer Institute Community Cancer Center, one of 30 in a national network of centers with a shared mission to expand research and care opportunities at hospitals serving largely rural, suburban, small town, and underserved populations.
As an NCCCP site, we will increase clinical trial access and availability and introduce Phase 1 trials usually done only at academic centers. Click here to learn more about NCCCP.
Clinical Trials at St. Luke's MSTI
Because
of its nationally
respected expertise,
St. Luke's MSTI is asked to participate in numerous clinical
research protocols in cooperation with regional and national
cancer research groups and pharmaceutical firms.
Among these research groups are the National Cancer Institute (NCI), Fred Hutchison Cancer Center, Mountain States Tumor and Medical Research Institute (MSTMRI), Children's Oncology Group, Puget Sound Oncology Consortium, and the Southwest Oncology Group, all of which share important information about the latest developments in cancer treatments that benefit patients.
Some of the most recent major clinical trials in which St. Luke's MSTI has participated include the following National Cancer Institute-sponsored studies:
PLCO (Prostate, Lung, Colorectal, and Ovarian) Cancer Screening Trial: 
St. Luke's MSTI
was selected to participate as a satellite of the University
of Utah in this long-term study, which was designed
to determine if screening tests intended to detect these
cancers at an early stage are able to reduce deaths. The trial will also help researchers
learn more about the causes of these cancers and how to
prevent them.
The screening component of the trial was completed in 2006. Participants are being followed and additional data will be collected through 2015. For more deatil about the study, visit cancer.gov and search by "PLCO."
National Lung Screening Trial (NLST): This study compared Spiral CT exams and chest X-rays as screening tools in the early detection of lung cancer in high-risk individuals. Participants (long-term smokers) were randomized into one of two arms – spiral CT or chest X-ray. The NLST was initiated in 2002 and closed to enrollment in 2004, with 1,620 participants. Each participant received three exams over two years.
On June 29, 2011, the primary results were published online in the New England Journal of Medicine and appeared in the print issue on August 4, 2011. These findings reveal that participants who received low-dose helical CT scans had a 20 percent lower risk of dying from lung cancer than participants who received standard chest X-rays. For more deatil about the study and its results, visit cancer.gov and search by "NLST."
SELECT (Selenium and Vitamin E Cancer Prevention Trial): The largest cancer prevention trial ever undertaken, SELECT evaluated the affect of selenium and vitamin E in the prevention of prostate cancer. The study enrolled 35,534 male patients from 2001-2004, and followed them for several years to determine the impact of treatment on the likelihood of development of prostate cancer.
Initial data in 2008 showed that daily selenium and vitamin in E supplements, taken either alone or together for a median of 5.5 years, did not prevent prostate cancer. Updated data in 2011 showed that after an average of 7 years (5.5 years on supplements and 1.5 off supplements), there were 17 percent more cases of prostate cancer in men taking only vitamin E than in men taking only placebos.
For more deatil about the study and its results, visit cancer.gov and search by "Selenium and Vitamin E Cancer Prevention Trial."
Interested in clinical trials?
St. Luke's MSTI is pleased to offer TrialCheck ®.
TrialCheck is a free comprehensive searchable database of cancer clinical trials
that offers the very latest in treatment information.
With TrialCheck, patients and caregivers can easily locate clinical trials based on patient-specific criteria such as cancer types, stage, previous treatment, daily activity, and zip code.
Learn more about research at St. Luke's
